Search Results

Your search for Suresh S. Ramalingam, MD matches 22 pages

Showing 1 - 22

lung cancer

Evidence Builds for Tumor Mutational Burden as Biomarker in Lung Cancer

TUMOR MUTATIONAL burden is emerging as a predictive biomarker for the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) in non–small cell lung cancer (NSCLC), as well as other tumor types. However, experts say tumor mutational burden has hurdles to overcome. At the 2018 Annual Meeting of...

lung cancer

Osimertinib: A New Standard of Care in Initial Treatment of EGFR-Mutant NSCLC

Dr. Ramalingam is Professor of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta. MUTATIONS IN the epidermal growth factor receptor (EGFR) gene were discovered in 2004. These mutations, localized most commonly to exon 19 or 21, vary in...

lung cancer

‘Clinically Meaningful’ Results With First-Line Osimertinib in EGFR–Positive NSCLC

OSIMERTINIB (TAGRISSO) showed encouraging results as first-line therapy for patients with epidermal growth factor receptor (EGFR)–mutated non–small-cell lung cancer (NSCLC) in the phase III FLAURA trial, according to results presented at the 2017 European Society for Medical Oncology (ESMO)...

lung cancer

Osimertinib in First-Line Treatment of EGFR Mutation–Positive Advanced NSCLC

Osimertinib (Tagrisso) has shown high activity in the phase I expansion component of the AURA trial in previously untreated patients with EGFR mutation–positive advanced non–small cell lung cancer (NSCLC). These findings were reported by Ramalingam et al in the Journal of Clinical...

lung cancer

Non–Small Cell Lung Cancer: Emerging Concepts for Checkpoint Inhibitors

With checkpoint inhibitors vitally important in the treatment of advanced non–small cell lung cancer (NSCLC), clinicians must become familiar with the nuances of their use. At the 2017 Debates and Didactics in Hematology and Oncology Conference in Sea Island, Georgia, Suresh S. Ramalingam, MD,...

Promoting Physician Wellness: An Overview of ASCO Initiatives

Suresh S. Ramalingam, MD Professor of Hematology and Medical Oncology, Director of Medical Oncology, Assistant Dean for Cancer Research, Emory University School of Medicine; Roberto C. Goizueta Distinguished Chair in Cancer Research, Deputy Director, Winship Cancer Institute ASCO Member since ...

lung cancer

Experts Consider the New Immunotherapy Paradigm in Advanced Lung Cancer

One immune checkpoint inhibitor has now moved to the front of the line for treating advanced non–small cell lung cancer (NSCLC). Based on pivotal studies presented at the 2016 European Society for Medical Oncology (ESMO) Congress, pembrolizumab (Keytruda) became a first-line option, and it is...

Suresh S. Ramalingam, MD, Honored With Goizueta Chair for Cancer Research at Winship Cancer Institute

Suresh S. Ramalingam, MD, Deputy Director of Winship Cancer Institute of Emory University and Assistant Dean for Cancer Research in the Emory School of Medicine, was honored with the Roberto C. Goizueta Distinguished Chair for Cancer Research. The endowment was established to support a key leader...

issues in oncology
solid tumors
hematologic malignancies

How Immunotherapy Is Revolutionizing Cancer Care

More than 100 years after ­William B. Coley, MD, used bacterial toxins to goad the immune system into recognizing cancer cells as foreign to the body and mount an immune response to go after and kill them, the recognition of immunotherapy as a powerful anticancer therapy is finally being...

lung cancer

ELCC 2016: Osimertinib Given as First-Line Treatment May Alter Biology of EGFR-Mutated Non–Small Cell Lung Cancer

The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib (Tagrisso) is effective in the first-line treatment of EGFR-mutated non­­–small cell lung cancer (NSCLC), according to a late-breaking abstract presented by Ramalingam et al (Abstract...

lung cancer

Emerging Targeted Therapies Offer Glimmer of Hope for NSCLC but Biomarkers for Response Needed

Among the newer approaches to treatment of non–small cell lung cancer (NSCLC) are heat-shock protein 90 (Hsp90) inhibitors, toll-like receptor 2 (TLR2) agonists, and vascular-disrupting agents. So far, none appears to be a “home run,” but Hsp90 inhibition may be the most promising of the three...

lung cancer

First Positive Trial of Heat Shock Protein 90 Inhibitor in Lung Cancer That Has Progressed after First-line Therapy 

The investigational heat shock protein (Hsp)90 inhibitor ganetespib plus docetaxel extended overall survival compared with docetaxel alone as second-line therapy in patients with advanced non–small cell adenocarcinoma of the lung that had progressed on first-line therapy in the randomized phase II...

lung cancer

Hsp90 Inhibitors May Soon Transition Into Clinic

Inhibitors of heat shock protein 90 (Hsp90) look promising for the treatment of advanced non–small cell lung cancer (NSCLC) and have the advantage of not needing a specific mutation to target, said Suresh S. Ramalingam, MD, Professor and Chief of Medical Oncology at the Winship Cancer Institute of...

lung cancer

‘Clinically Meaningful Improvements’ in Survival for Patients With NSCLC When Veliparib Is Added to Carboplatin and Paclitaxel

Adding veliparib to carboplatin and paclitaxel resulted in “clinically meaningful improvements” in progression-free survival and overall survival among patients with previously untreated metastatic or advanced non–small cell lung cancer (NSCLC), particularly those with squamous histology. The...

lung cancer

Immune Checkpoint Inhibitors: The Dawn of a New Era for Lung Cancer Therapy

The therapeutic paradigm for lung cancer has changed rapidly over the past few years toward individualized therapy. For certain subsets of patients, molecularly targeted agents have resulted in robust gains in overall survival and quality of life. However, for the majority of patients with...

lung cancer
issues in oncology

Positioning Targeted and Immunotherapy-Based Approaches in Lung Cancer

With immunotherapy changing the face of lung cancer, is there still a place for targeted therapy? Two experts from Emory University debated this issue at the 2015 Debates and Didactics in Hematology and Oncology Conference held in Sea Island, Georgia. Fadlo Khuri, MD, was recently named President...

Charting a New Course: From Clinical Investigator to University President

What first intrigued Fadlo R. Khuri, MD, FACP, about the prospect of becoming the 16th President of the American University of Beirut (AUB) in Lebanon was the chance to give back to an institution and a country that had given him so much. Born in Boston, Massachusetts, in 1963, Dr. Khuri was raised ...

lung cancer

AZD9291 Updates Encouraging for Treatment-Resistant NSCLC

At the 16th World Conference on Lung Cancer, several studies showed consistent activity with the investigational third-generation inhibitor AZD9291 in patients with advanced non–small cell lung cancer (NSCLC) that is resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors....

lung cancer

Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC

In a phase II trial reported in Journal of Clinical Oncology, Ramalingam et al found that the addition of the VEGFR and PDGFR inhibitor linifanib to carboplatin-paclitaxel increased progression-free survival in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). The...

lung cancer

No Progression-Free Survival Benefit of Dacomitinib vs Erlotinib Overall or in KRAS Wild-Type Disease in Pretreated Advanced NSCLC

In a phase III ARCHER 1009 trial reported in The Lancet Oncology, Ramalingam et al found no progression-free survival benefit of the irreversible pan-HER tyrosine kinase inhibitor dacomitinib vs erlotinib among all patients with pretreated non–small cell lung cancer (NSCLC) or among those...

head and neck cancer

Long-Term Use of Valproic Acid May Reduce the Risk of Head and Neck Cancer

The antiseizure medication and mood stabilizer valproic acid was associated with a significant reduction in head and neck cancer risk, according to a study recently published in Cancer. The large retrospective cohort study by Kang et al was conducted to evaluate the effects of the drug, a histone...

lung cancer

ASCO 2013: Novel Heat Shock Protein Inhibitor Effective in Combination with Docetaxel as Second-line Therapy for Advanced Lung Cancer

A large randomized phase II study, GALAXY-1, found that a novel heat shock protein (Hsp) 90 inhibitor, ganetespib, when combined with docetaxel in second-line therapy, leads to longer overall survival compared to standard second-line docetaxel alone in patients with advanced lung adenocarcinoma...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.